Colorectal Cancer

Although many hate drinking the prep for colonoscopies, I view it as a privilege.

The Food and Drug Administration granted a priority review to Krazati plus Erbitux for KRAS G12C-mutant locally advanced or metastatic colorectal cancer.

I recently said goodbye to my oncologist of five years now that I have no evidence of colorectal cancer; it's time to let go.

Even though conquering cancer scared me, I knew being courageous would help me with the fight.

My wife's simple sentence to me ended up saving my life from colorectal cancer.

Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

Circulating tumor DNA-based minimal residual disease lent insight into which patients with stage 2/3 colorectal cancer may be at higher risk for recurrence and which could benefit from postsurgical chemotherapy.

Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab.

In patients with TRK fusion GI cancers, Vitrakvi continued to show improvements regarding responses to treatment, survival and safety, research found.

During the holiday season, the most important thing you can do for a patient with cancer is ‘hold space’ for them.

One of my favorite songs really hit home after I was diagnosed with cancer.

Adding one cup of navy beans per day to patients’ diets increased beneficial bacteria in the digestive system with no side effects, according to recent study findings.

The Food and Drug Administration approved six new cancer therapies in November 2023.

The recent approval of Fruzaqla (fruquintinib) for patients with pretreated metastatic colorectal cancer (mCRC) offers improved survival with manageable quality of life.

Patients with colorectal cancer who had diabetes with complications had an 85% higher risk of death than those without diabetes, according to the findings of a study.

As Georgetown women’s basketball couch Tasha Butts died from cancer and “The Walking Dead” actor Erik Jensen revealed cancer diagnosis, here is what’s happening in the oncology space this week.

Sometimes you just need to be present, whether that means being in the room or a phone call away.

Adding debulking surgery to chemotherapy did not cause a significant decrease in health-related quality of life for patients with metastatic colorectal cancer, research showed.

The recent FDA approval of Lonsurf plus Avastin for metastatic colorectal cancer improves survival and quality of life, an expert said.

A new finding can help predict whether patients with advanced colorectal cancer can benefit from receiving immunotherapy.

As majority leader Steve Scalise announces his new cancer diagnosis and author Ibram X. Kendi reveals that he is cancer free, this is what’s happening in the oncology space this week.

Becoming an advocate after my cancer diagnosis made an impact not only on others, but for myself.

The Food and Drug Administration has approved the combination of Lonsurf and Avastin for patients with metastatic colorectal cancer previously treated with chemotherapies, an anti-VEGF therapy and, if RAS wild-type, an anti-EGFR therapy.

If it wasn’t for my friends and family, I don’t know how I would have gotten through cancer alone.

We recently asked our audience of patients, survivors and caregivers about the ongoing cisplatin and carboplatin shortage. Here’s what they had to say.

Having a strong connection with their care team can be crucial for the well-being of LGBTQ+ patients with cancer, as a colorectal cancer survivor and surgeon from City of Hope told CURE®.

Implementing longer intervals between the completion of neoadjuvant therapy and surgery may have a positive effect on pathologic complete responses for patients with locally advanced rectal cancer.

When it comes to a physical exam, you don’t know how much of an impact it could make.

Patients with non-microsatellite instability-high metastatic colorectal cancer had better survival rates from the botensilimab and balstilimab combination.

Recent research found that patients who supplemented their vitamin D intake tended to have improved colorectal cancer outcomes.